RFK Jr. promised to stop the ‘aggressive suppression’ of these controversial drugs. He’s making progress.

Health Secretary Robert F. Kennedy Jr. is moving to shift how the Food and Drug Administration handles peptides. During a two-day meeting this week, an advisory committee recommended that the agency allow compounding pharmacies to manufacture several types of peptides for patients with prescriptions. This move aims to expand access to substances often promoted by wellness influencers for weight loss and physical recovery.

FDA staff members previously warned of insufficient evidence regarding the safety and efficacy of these substances. Despite these warnings, the advisory committee largely bypassed agency staff input. The committee currently includes several new members who have publicly expressed support for loosening current restrictions.

Proponents of the policy argue that widespread public demand already exists for peptides. They maintain that legalizing production through licensed pharmacies will reduce the risks associated with the current unregulated market. Critics, including former agency officials and pharmaceutical industry representatives, argue that this decision bypasses traditional clinical trial requirements and creates significant safety risks for consumers.

While the advisory committee’s vote is not binding, it marks a significant shift in direction for the agency. Final authority rests with Secretary Kennedy, who has the power to overrule the FDA’s previous stance. The debate highlights a conflict between immediate consumer access and established regulatory standards for drug safety.

Telehealth firms and compounding pharmacies are already preparing for potential approval. If these companies begin mass manufacturing peptides, it would represent a departure from how the agency historically manages pharmaceutical approvals. The situation remains in flux as the FDA weighs the committee’s recommendations against existing safety data.